What is BioVie, Inc.'s earnings per share (EPS)?

BioVie, Inc. (BIVI) reported diluted earnings per share of -$3.05 for fiscal year 2026. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

BioVie, Inc. (BIVI) Financials

BIVI

FY2026 annual

Revenue Not reported for FY2026

Net Income -$22.1M -25.8% YoY

EPS (Diluted) -$3.05 YoY not available

Operating Cash Flow -$19.0M 0.0% YoY

Market Cap $12.7M as of Oct 3, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2026

Price / Book 1.2x on $10.3M equity, Q4 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period FY2026, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE June

Newest figures come from the 10-K for FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BIVI SEC filings page.

This page shows BioVie, Inc. (BIVI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BIVI FY2026 2026-10-03

BioVie remains a development-stage business: research spending and recurring cash needs are financed mainly through external capital.

From FY2025 to FY2026, research and development increased to $14.0M while operating cash flow remained an outflow of $19.0M. That pairing, alongside a net loss of $22.1M in FY2026, indicates the cash requirement is persistent rather than tied only to one year of elevated research spending.

By FY2026, total liabilities were $4.0M and debt-to-equity was 0.4x, so the company is not relying heavily on debt financing. Yet total assets fell to $14.3M while the current ratio was 3.6x, meaning the improved leverage profile coexists with a smaller balance-sheet cushion.

Financing cash inflows declined from $17.8M in FY2024 to $10.5M in FY2026 while operating cash flow remained negative, showing external funding is still part of the operating model. Reported liquidity equaled 5.7 months of the latest annual operating outflow, a comparison of resources with a recent cash-use rate rather than a forecast.

Financial Health Signals

Financial health score not available

BioVie, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/6

BioVie, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing

N/A

BioVie, Inc. reported a net loss of $22.1M while operations used $19.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

BioVie, Inc. reported an operating loss of $22.7M against $18K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EPS (Diluted)

-$0.70

YoY+51.4%

QoQ0.0%

BioVie, Inc. earned -$0.70 per diluted share (EPS) in Q4 2026. This represents an increase of 51.4% from the same quarter a year earlier. It is unchanged from the prior quarter.

Revenue

Not reported for Q4 2026.

EBITDA

Not reported for Q4 2026.

Net Income

Not reported for Q4 2026.

Cash & Balance Sheet

Cash & Debt

$9.0M

YoY-48.8%

QoQ-31.5%

5Y CAGR+14.8%

10Y CAGR+53.5%

BioVie, Inc. held $9.0M in cash as of Q4 2026; long-term debt is not reported for that period.

Shares Outstanding

YoY+0.1%

QoQ0.0%

5Y CAGR-21.2%

10Y CAGR-21.7%

BioVie, Inc. had 8M shares outstanding in Q4 2026. This represents an increase of 0.1% from the same quarter a year earlier. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q4 2026.

Dividends Per Share

Not reported for Q4 2026.

Margins & Returns

None of these metrics is reported for Q4 2026.

Capital Allocation

None of these metrics is reported for Q4 2026.

BIVI Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BIVI quarterly income statement

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1410-K
R&D Expenses	$14.0M+50.7%	$9.3M-59.9%	$23.1M-30.6%	$33.3M+92.9%	$17.3M+578.2%	$2.5M+121.2%	$1.2M+14.1%	$1.0M+171.8%	$371K-20.5%	$466K+1130.5%	$38K+803.3%	$4K-91.5%	$49K	$49K
SG&A Expenses	$8.5M-0.7%	$8.6M-3.2%	$8.8M-23.4%	$11.6M+18.3%	$9.8M+110.6%	$4.6M+253.2%	$1.3M+4.3%	$1.3M-28.9%	$1.8M+2463.5%	$69K+351.2%	$15K-7.0%	$16K-36.4%	$26K	$117K
Operating Income	-$22.7M-25.4%	-$18.1M+43.9%	-$32.2M+28.6%	-$45.1M-65.4%	-$27.3M	N/A	-$2.7M-7.9%	-$2.5M-5.2%	-$2.4M-52.7%	-$1.6M-259.6%	-$432K-85.1%	-$233K	N/A	N/A
Interest Expense	$18K-94.6%	$333K-88.5%	$2.9M-32.7%	$4.3M+98.8%	$2.2M+286.6%	$559K-88.3%	$4.8M+1748042.5%	$273-99.3%	$41K	N/A	$81	N/A	N/A	N/A
Net Income	-$22.1M-25.8%	-$17.5M+45.4%	-$32.1M+36.1%	-$50.3M-92.7%	-$26.1M	N/A	N/A	-$2.4M-0.4%	-$2.4M-82.9%	-$1.3M-208.1%	-$432K-85.4%	-$233K+27.6%	-$322K	-$166K
EPS (Basic)	-$3.05+74.8%	-$12.12+83.4%	-$73.05-372.2%	-$15.47-1359.4%	-$1.06+92.8%	-$14.82-116.4%	-$6.85-599.0%	-$0.98	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$3.05	-$12.12	-$73.05	-$15.47	-$1.06+92.8%	-$14.82	-$6.85	-$0.98	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	7M	1M	451,853	3M	25M+98.8%	12M	5M	3M	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'2610-K	Q3'2610-K	Q2'2610-K	Q1'2610-K	Q4'2510-K	Q3'2510-K	Q2'2510-K	Q1'2510-K
R&D Expenses	N/A	$3.2M+136.2%	$4.3M-9.3%	$2.9M+47.5%	N/A	$1.3M-76.4%	$4.7M-27.3%	$2.0M-77.6%
SG&A Expenses	N/A	$2.2M+35.6%	$1.9M-23.5%	$2.3M+10.4%	N/A	$1.6M-19.7%	$2.5M+12.3%	$2.1M+6.8%
Operating Income	N/A	-$5.4M-80.2%	-$6.3M+14.1%	-$5.3M-28.2%	N/A	-$3.0M+61.4%	-$7.3M+17.0%	-$4.1M+62.1%
Interest Expense	N/A	$6K+19.4%	$6K-91.1%	$2K-99.2%	N/A	$5K-99.2%	$67K-91.9%	$256K-74.5%
Net Income	N/A	-$5.3M-89.0%	-$6.1M+14.7%	-$5.1M-22.5%	N/A	-$2.8M+65.4%	-$7.1M+15.3%	-$4.2M+61.2%
EPS (Basic)	-$0.70+51.4%	-$0.70+53.6%	-$0.77+83.1%	-$0.98+86.0%	-$1.44+97.8%	-$1.51+24.5%	-$4.55-106.8%	-$7.00-139.7%
EPS (Diluted)	-$0.70+51.4%	-$0.70	-$0.77	-$0.98	-$1.44+97.8%	-$1.51	-$4.55	-$7.00
Diluted Shares (Avg)	N/A	8M	8M	5M	N/A	2M	2M	639,836

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Income Tax.

BIVI Balance Sheet

BIVI quarterly balance sheet

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1410-K
Total Assets	$14.3M-33.9%	$21.6M-14.5%	$25.2M-28.2%	$35.1M+74.5%	$20.1M+232.7%	$6.0M+190.2%	$2.1M-19.1%	$2.6M+18.3%	$2.2M-8.0%	$2.4M-13.1%	$2.7M+909.0%	$269K-19.0%	$333K	$360K
Current Assets	$13.6M-34.1%	$20.7M-13.9%	$24.0M-29.4%	$34.0M+81.3%	$18.8M+307.8%	$4.6M+1015.1%	$413K-38.7%	$674K+1371.8%	$46K+791.1%	$5K-96.1%	$131K-51.5%	$269K-19.0%	$333K	$360K
Cash & Equivalents	$9.0M-48.8%	$17.5M-26.4%	$23.8M+22.5%	$19.5M+4.4%	$18.6M+313.2%	$4.5M+12029.7%	$37K-89.1%	$340K+642.2%	$46K+791.1%	$5K-95.8%	$124K-53.7%	$267K-19.6%	$333K	$345K
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A
Goodwill	$346K0.0%	$346K0.0%	$346K0.0%	$346K0.0%	$346K0.0%	$346K0.0%	$346K0.0%	$346K0.0%	$346K0.0%	$346K0.0%	$346K	N/A	N/A	N/A
Total Liabilities	$4.0M+56.1%	$2.6M-73.7%	$9.7M-50.9%	$19.8M+20.2%	$16.4M+1550.4%	$996K-95.8%	$23.6M+5217.6%	$443K-78.5%	$2.1M+71.0%	$1.2M+50.3%	$803K+148.2%	$324K+100.4%	$161K	$3K
Current Liabilities	$3.8M+66.9%	$2.3M-75.7%	$9.4M-35.5%	$14.5M+247.7%	$4.2M+318.4%	$996K-95.8%	$23.5M+5203.5%	$443K-64.2%	$1.2M+96.3%	$631K-21.4%	$803K+148.2%	$324K+100.4%	$161K	$3K
Non-Current Liabilities	$184K-33.0%	$275K-21.3%	$350K-93.4%	$5.3M-57.1%	$12.3M	$0-100.0%	$63K	$0-100.0%	$826K+43.4%	$576K	$0	$0	$0	$0
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	$63K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$10.3M-46.0%	$19.0M+22.6%	$15.5M+1.1%	$15.3M+317.9%	$3.7M-27.3%	$5.1M+123.5%	-$21.5M-1108.9%	$2.1M+1816.3%	$111K-90.4%	$1.2M-39.6%	$1.9M+3640.2%	-$54K-131.6%	$171K	$357K
Retained Earnings	-$374.3M-6.3%	-$352.1M-5.4%	-$334.2M-11.0%	-$301.2M-20.0%	-$251.0M-11.6%	-$224.9M-448.0%	-$41.0M-465.1%	-$7.3M-52.3%	-$4.8M-104.2%	-$2.3M-132.5%	-$1.0M-75.5%	-$572K	N/A	N/A

Metric	Q4'2610-K	Q3'2610-K	Q2'2610-K	Q1'2610-K	Q4'2510-K	Q3'2510-K	Q2'2510-K	Q1'2510-K
Total Assets	$14.3M-33.9%	$17.5M-29.0%	$22.5M-12.4%	$26.8M+26.3%	$21.6M-14.5%	$24.7M-22.4%	$25.7M+19.6%	$21.2M-10.6%
Current Assets	$13.6M-34.1%	$16.9M-28.8%	$21.8M-11.7%	$26.0M+29.2%	$20.7M-13.9%	$23.7M-22.3%	$24.7M+20.0%	$20.2M-11.5%
Cash & Equivalents	$9.0M-48.8%	$13.1M-43.4%	$20.5M-15.8%	$25.0M+24.7%	$17.5M-26.4%	$23.2M-23.7%	$24.4M+20.7%	$20.0M-5.6%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$346K0.0%	$346K0.0%	$346K0.0%	$346K0.0%	$346K0.0%	$346K0.0%	$346K0.0%	$346K0.0%
Total Liabilities	$4.0M+56.1%	$1.9M-32.9%	$3.2M+82.8%	$1.9M-73.5%	$2.6M-73.7%	$2.8M-77.9%	$1.8M-87.3%	$7.2M-55.8%
Current Liabilities	$3.8M+66.9%	$1.7M-33.5%	$3.0M+106.3%	$1.6M-75.9%	$2.3M-75.7%	$2.5M-79.6%	$1.5M-89.6%	$6.8M-48.2%
Non-Current Liabilities	$184K-33.0%	$213K-27.9%	$233K-26.2%	$254K-23.5%	$275K-21.3%	$296K-19.3%	$315K+1688.9%	$333K-88.9%
Total Equity	$10.3M-46.0%	$15.6M-28.5%	$19.3M-19.5%	$24.9M+77.2%	$19.0M+22.6%	$21.8M+15.3%	$23.9M+219.3%	$14.1M+86.4%
Retained Earnings	-$374.3M-6.3%	-$368.6M-5.7%	-$363.3M-5.1%	-$357.3M-5.5%	-$352.1M-5.4%	-$348.7M-5.9%	-$345.9M-8.0%	-$338.7M-8.6%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Long-Term Debt.

BIVI Cash Flow Statement

BIVI quarterly cash flow statement

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1410-K
Operating Cash Flow	-$19.0M0.0%	-$19.0M+31.9%	-$27.9M+30.6%	-$40.3M-112.0%	-$19.0M-81.7%	-$10.5M-542.0%	-$1.6M+34.9%	-$2.5M-302.6%	-$621K+0.4%	-$624K-305.9%	-$154K-135.0%	-$65K+62.2%	-$173K	-$163K
Stock-Based Compensation	$2.3M+91.0%	$1.2M-57.7%	$2.8M-33.1%	$4.2M-27.3%	$5.8M+92.3%	$3.0M+12054.1%	$25K-61.7%	$65K-72.8%	$238K	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	$14.5M+201.6%	-$14.3M	N/A	N/A	N/A	N/A	N/A	N/A	$10K	N/A	N/A	N/A
Financing Cash Flow	$10.5M-17.8%	$12.7M-28.5%	$17.8M-67.8%	$55.4M+67.2%	$33.1M+121.9%	$14.9M+1026.2%	$1.3M-52.6%	$2.8M+322.3%	$662K+31.1%	$505K+10100080.0%	-$5	N/A	N/A	$508K
Dividends Paid	$44K-88.2%	$369K-58.3%	$886K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'2610-K	Q3'2610-K	Q2'2610-K	Q1'2610-K	Q4'2510-K	Q3'2510-K	Q2'2510-K	Q1'2510-K
Operating Cash Flow	-$4.1M+26.5%	-$7.4M-493.7%	-$4.4M+48.3%	-$3.0M+15.5%	-$5.6M-40.0%	-$1.3M+78.6%	-$8.6M-45.3%	-$3.6M+70.6%
Stock-Based Compensation	N/A	N/A	N/A	$268K+125.7%	N/A	N/A	N/A	$119K-85.3%
Financing Cash Flow	$0	$0	$0-100.0%	$10.5M+4440.4%	$0+100.0%	$0-100.0%	$13.0M+163.5%	-$241K+59.4%
Dividends Paid	N/A	N/A	N/A	$44K-86.6%	$0	$0	$44K	$325K

Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Share Buybacks.

BIVI Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BIVI quarterly financial ratios

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1410-K
Return on Equity	-214.9%-122.7pp	-92.3%+114.9pp	-207.1%+120.5pp	-327.6%+383.0pp	-710.6%	N/A	N/A	-114.7%+2074.3pp	-2189.0%-2074.0pp	-115.0%-92.4pp	-22.5%	N/A	-187.8%	-46.5%
Return on Assets	-154.9%-73.5pp	-81.4%+46.1pp	-127.4%+15.7pp	-143.2%-13.5pp	-129.7%	N/A	N/A	-95.0%+16.9pp	-111.9%-55.6pp	-56.3%-40.4pp	-15.9%+70.6pp	-86.5%+10.2pp	-96.7%	-46.2%
Current Ratio	3.59-5.5x	9.10+6.5x	2.57+0.2x	2.35-2.2x	4.50-0.1x	4.62+4.6x	0.02-1.5x	1.52+1.5x	0.040.0x	0.01-0.2x	0.16-0.7x	0.83-1.2x	2.06	143.81
Debt-to-Equity	0.39+0.3x	0.13-0.5x	0.63-0.7x	1.29-3.2x	4.48+4.3x	0.20	N/A	0.21-18.4x	18.56+17.5x	1.04+0.6x	0.42	N/A	0.94	0.01

Metric	Q4'2610-K	Q3'2610-K	Q2'2610-K	Q1'2610-K	Q4'2510-K	Q3'2510-K	Q2'2510-K	Q1'2510-K
Return on Equity	N/A	-33.8%-21.0pp	-31.5%-1.8pp	-20.4%+9.1pp	N/A	-12.8%+29.8pp	-29.7%+82.4pp	-29.5%+112.4pp
Return on Assets	N/A	-30.1%-18.8pp	-27.0%+0.7pp	-19.0%+0.6pp	N/A	-11.3%+14.1pp	-27.7%+11.4pp	-19.6%+25.5pp
Current Ratio	3.59-5.5x	9.97+0.7x	7.25-9.7x	15.83+12.9x	9.10+6.5x	9.32+6.9x	16.94+15.5x	2.95+1.2x
Debt-to-Equity	0.39+0.3x	0.120.0x	0.17+0.1x	0.08-0.4x	0.13-0.5x	0.13-0.5x	0.07-1.8x	0.51-1.6x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
BioVie, Inc. BIVI	FY2026	N/A	-$22.1M	N/A	$12.7M	—
Minerva Neurosciences, Inc NERV	FY2025	N/A	-$293.4M	N/A	$156.6M	—
NextCure, Inc. NXTC	FY2025	N/A	-$55.8M	N/A	$23.3M	—
Imunon, Inc. IMNN	FY2025	N/A	$14.5M	N/A	$7.2M	—
MetaVia Inc. MTVA	FY2025	N/A	-$13.0M	N/A	$10.1M	—
Briacell Therapeutics Corp. BCTX	FY2025	N/A	-$26.3M	N/A	$35.1M	—

Where BioVie, Inc. Ranks

Frequently Asked Questions

Is BioVie, Inc. profitable?

No, BioVie, Inc. (BIVI) reported a net income of -$22.1M in fiscal year 2026.

What is BioVie, Inc.'s return on equity (ROE)?

BioVie, Inc. (BIVI) has a return on equity of -214.9% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is BioVie, Inc.'s operating cash flow?

BioVie, Inc. (BIVI) recorded an outflow of $19.0M in operating cash flow during fiscal year 2026, representing cash used by core business activities.

What are BioVie, Inc.'s total assets?

BioVie, Inc. (BIVI) had $14.3M in total assets as of fiscal year 2026, including both current and long-term assets.

How much does BioVie, Inc. spend on research and development?

BioVie, Inc. (BIVI) invested $14.0M in research and development during fiscal year 2026.

How many shares does BioVie, Inc. have outstanding?

BioVie, Inc. (BIVI) had 8M shares outstanding as of fiscal year 2026.

What is BioVie, Inc.'s current ratio?

BioVie, Inc. (BIVI) had a current ratio of 3.59 as of fiscal year 2026, which is generally considered healthy.

What is BioVie, Inc.'s debt-to-equity ratio?

BioVie, Inc. (BIVI) had a debt-to-equity ratio of 0.39 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is BioVie, Inc.'s return on assets (ROA)?

BioVie, Inc. (BIVI) had a return on assets of -154.9% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is BioVie, Inc.'s P/E ratio?

BioVie, Inc. (BIVI) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2026). The market capitalization is $12.7M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is BioVie, Inc.'s price-to-sales ratio?

BioVie, Inc. (BIVI) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $12.7M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does BioVie, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2026, BioVie, Inc. (BIVI) held $9.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $19.0M over that year. Dividing the one by the other, the reported balance equals about 6 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is BioVie, Inc.'s Piotroski F-Score?

BioVie, Inc. (BIVI) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are BioVie, Inc.'s earnings high quality?

BioVie, Inc. (BIVI) reported a net loss of $22.1M while operations used $19.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can BioVie, Inc. cover its interest payments?

BioVie, Inc. (BIVI) reported an operating loss of $22.7M against $18K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.